A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

PHASE3CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

April 20, 2022

Study Completion Date

April 20, 2022

Conditions
Hot Flashes
Interventions
DRUG

Fezolinetant

Oral

DRUG

Placebo

Oral

Trial Locations (48)

Unknown

Site CN86001, Beijing

Site CN86002, Beijing

Site CN86017, Beijing

Site CN86030, Beijing

Site CN86022, Changchun

Site CN86009, Changsha

Site CN86037, Chengdu

Site CN86006, Guangzhou

Site CN86019, Guangzhou

Site CN86042, Guangzhou

Site CN86043, Guangzhou

Site CN86018, Guiyang

Site CN86025, Hangzhou

Site CN86034, Hangzhou

Site CN86027, Kunming

Site CN86005, Liuzhou

Site CN86004, Nanjing

Site CN86011, Nanjing

Site CN86035, Nanjing

Site CN86026, Nanning

Site CN86012, Shanghai

Site CN86021, Shenzhen

Site CN86007, Shijiazhuang

Site CN86023, Taiyuan

Site CN86031, Taiyuan

Site CN86015, Tianjin

Site CN86029, Tianjin

Site CN86008, Wuhan

Site CN86041, Yangzhou

Site CN86013, Yinchuan

Site CN86033, Zhongshan

Site KR82013, Ansan-si

Site KR82005, Busan

Site KR82003, Seongnam-si

Site KR82011, Seongnam-si

Site KR82001, Seoul

Site KR82002, Seoul

Site KR82004, Seoul

Site KR82006, Seoul

Site KR82012, Seoul

Site TW88608, Kaohsiung City

Site TW88604, New Taipei City

Site TW88606, Taichung

Site TW88603, Tainan City

Site TW88609, Tainan City

Site TW88601, Taipei

Site TW88607, Taipei

Site TW88611, Taipei

All Listed Sponsors
lead

Astellas Pharma China, Inc.

INDUSTRY

NCT04234204 - A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause | Biotech Hunter | Biotech Hunter